NASDAQ:NEPTNeptune Wellness Solutions Stock Price, Forecast & News

Neptune Wellness Solutions' stock was trading at $1.21 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, NEPT shares have increased by 161.2% and is now trading at $3.16. View which stocks have been most impacted by Coronavirus.

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Neptune Wellness Solutions in the last year. There are currently 1 hold rating and 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Neptune Wellness Solutions.

Neptune Wellness Solutions is scheduled to release its next quarterly earnings announcement on Wednesday, June 10th 2020. View our earnings forecast for Neptune Wellness Solutions.

Neptune Wellness Solutions will be holding an earnings conference call on Wednesday, June 10th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

Neptune Wellness Solutions Inc (NASDAQ:NEPT) announced its earnings results on Wednesday, October, 12th. The biotechnology company reported ($0.02) earnings per share (EPS) for the quarter. The biotechnology company earned $8.91 million during the quarter. Neptune Wellness Solutions had a negative net margin of 132.09% and a negative return on equity of 39.22%. View Neptune Wellness Solutions' earnings history.

Neptune Wellness Solutions updated its first quarter 2021 IntraDay earnings guidance on Thursday, May, 14th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $18-22 million.

3 Wall Street analysts have issued 1 year target prices for Neptune Wellness Solutions' shares. Their forecasts range from $3.75 to $3.75. On average, they expect Neptune Wellness Solutions' stock price to reach $3.75 in the next twelve months. This suggests a possible upside of 18.7% from the stock's current price. View analysts' price targets for Neptune Wellness Solutions.

News coverage about NEPT stock has trended positive recently, InfoTrie reports. The research group identifies positive and negative news coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. Neptune Wellness Solutions earned a news sentiment score of 3.0 on InfoTrie's scale. They also assigned media headlines about the biotechnology company a news buzz of 4.0 out of 10, meaning that recent news coverage is somewhat unlikely to have an effect on the stock's share price in the near term. View the latest news aboutNeptune Wellness Solutions.

Neptune Wellness Solutions saw a increase in short interest during the month of May. As of May 15th, there was short interest totaling 8,430,000 shares, an increase of 14.1% from the April 30th total of 7,390,000 shares. Based on an average daily trading volume, of 1,310,000 shares, the short-interest ratio is currently 6.4 days. Approximately 11.0% of the shares of the stock are short sold. View Neptune Wellness Solutions' Current Options Chain.

Some companies that are related to Neptune Wellness Solutions include Cytokinetics (CYTK), Mersana Therapeutics (MRSN), Phibro Animal Health (PAHC), Passage Bio (ORIC), Enanta Pharmaceuticals (ENTA), Athenex (ATNX), MacroGenics (MGNX), Rocket Pharmaceuticals (RCKT), Applied Therapeutics (APLT), Endo International (ENDP), BioXcel Therapeutics (BTAI), Stoke Therapeutics (STOK), Amphastar Pharmaceuticals (AMPH), Rhythm Pharmaceuticals (RYTM) and Gossamer Bio (GOSS). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Neptune Wellness Solutions investors own include Canopy Growth (CGC), Tilray (TLRY), Aurora Cannabis (ACB), Cronos Group (CRON), Amarin (AMRN), Zynerba Pharmaceuticals (ZYNE), Aphria (APHA), Cara Therapeutics (CARA), Crispr Therapeutics (CRSP) and Sangamo Therapeutics (SGMO).

Neptune Wellness Solutions trades on the NASDAQ under the ticker symbol "NEPT."

Neptune Wellness Solutions' stock is owned by many different institutional and retail investors. Top institutional investors include AdvisorShares Investments LLC (0.42%), Deutsche Bank AG (0.24%), White Pine Capital LLC (0.12%) and Two Sigma Investments LP (0.06%).

NEPT stock was bought by a variety of institutional investors in the last quarter, including Deutsche Bank AG, Two Sigma Investments LP, White Pine Capital LLC, and AdvisorShares Investments LLC.

Shares of NEPT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of NEPT stock can currently be purchased for approximately $3.16.

Neptune Wellness Solutions has a market capitalization of $300.39 million and generates $18.39 million in revenue each year. The biotechnology company earns $-17,670,000.00 in net income (profit) each year or ($0.14) on an earnings per share basis. Neptune Wellness Solutions employs 58 workers across the globe.

The official website for Neptune Wellness Solutions is www.neptunecorp.com.

Neptune Wellness Solutions' mailing address is 545 PROMENADE DU CENTROPOLIS SUITE 100, LAVAL A8, H7T 0A3. The biotechnology company can be reached via phone at 45-0687-2262 or via email at [email protected]